Trade Corbus Pharmaceuticals Holdings, Inc. - CRBP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.412 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Corbus Pharmaceuticals Holdings Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 6.264 |
| Open* | 6.444 |
| 1-Year Change* | 3853.37% |
| Day's Range* | 5.944 - 6.484 |
| 52 wk Range | 2.11-13.17 |
| Average Volume (10 days) | 11.97K |
| Average Volume (3 months) | 307.83K |
| Market Cap | 31.23M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 4.42M |
| Revenue | N/A |
| EPS | -11.02 |
| Dividend (Yield %) | N/A |
| Beta | 2.29 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 25, 2023 | 5.944 | -0.500 | -7.76% | 6.444 | 6.584 | 5.944 |
| Sep 22, 2023 | 6.264 | -0.180 | -2.79% | 6.444 | 6.814 | 6.224 |
| Sep 21, 2023 | 6.324 | -0.130 | -2.01% | 6.454 | 6.754 | 6.164 |
| Sep 20, 2023 | 6.454 | 0.080 | 1.26% | 6.374 | 6.704 | 6.374 |
| Sep 19, 2023 | 6.594 | -0.210 | -3.09% | 6.804 | 7.044 | 6.594 |
| Sep 18, 2023 | 6.804 | 0.210 | 3.18% | 6.594 | 7.054 | 6.374 |
| Sep 15, 2023 | 6.944 | 0.360 | 5.47% | 6.584 | 6.954 | 6.414 |
| Sep 14, 2023 | 6.734 | 0.150 | 2.28% | 6.584 | 6.844 | 6.454 |
| Sep 13, 2023 | 6.474 | -0.130 | -1.97% | 6.604 | 6.884 | 6.394 |
| Sep 12, 2023 | 6.454 | 0.000 | 0.00% | 6.454 | 6.884 | 6.454 |
| Sep 11, 2023 | 6.464 | 0.080 | 1.25% | 6.384 | 6.884 | 6.274 |
| Sep 8, 2023 | 6.434 | -0.130 | -1.98% | 6.564 | 6.934 | 6.344 |
| Sep 7, 2023 | 6.704 | 0.210 | 3.23% | 6.494 | 6.984 | 6.234 |
| Sep 6, 2023 | 6.444 | 0.220 | 3.53% | 6.224 | 6.854 | 6.224 |
| Sep 5, 2023 | 6.384 | -0.040 | -0.62% | 6.424 | 6.584 | 6.384 |
| Sep 1, 2023 | 6.444 | -0.510 | -7.33% | 6.954 | 6.994 | 6.444 |
| Aug 31, 2023 | 6.624 | -0.130 | -1.92% | 6.754 | 7.244 | 6.224 |
| Aug 30, 2023 | 6.674 | -0.220 | -3.19% | 6.894 | 6.944 | 6.594 |
| Aug 29, 2023 | 6.674 | 0.170 | 2.61% | 6.504 | 6.974 | 6.504 |
| Aug 28, 2023 | 6.704 | 0.270 | 4.20% | 6.434 | 6.984 | 6.224 |
Corbus Pharmaceuticals Holdings, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 13:05 | Country US
| Event Q3 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release Q3 2023 Corbus Pharmaceuticals Holdings Inc Earnings ReleaseForecast -Previous - |
| Tuesday, March 5, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0.88171 | 3.93723 | 36.1436 | 4.82227 |
| Revenue | 0 | 0.88171 | 3.93723 | 36.1436 | 4.82227 |
| Total Operating Expense | 39.8354 | 56.8707 | 126.747 | 113.248 | 61.57 |
| Selling/General/Admin. Expenses, Total | 18.6986 | 20.4254 | 28.4802 | 23.6434 | 12.956 |
| Research & Development | 16.1368 | 36.4453 | 98.2672 | 89.6048 | 48.614 |
| Operating Income | -39.8354 | -55.989 | -122.81 | -77.1046 | -56.7477 |
| Interest Income (Expense), Net Non-Operating | -2.46268 | -1.5514 | -1.72936 | 1.06902 | 1.07557 |
| Net Income Before Taxes | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Net Income After Taxes | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Net Income Before Extra. Items | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Net Income | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Income Available to Common Excl. Extra. Items | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Income Available to Common Incl. Extra. Items | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Diluted Net Income | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Diluted Weighted Average Shares | 4.17068 | 4.09967 | 2.60444 | 2.12976 | 1.8998 |
| Diluted EPS Excluding Extraordinary Items | -10.1535 | -11.1327 | -42.7229 | -33.5501 | -29.3042 |
| Diluted Normalized EPS | -8.95464 | -10.9849 | -42.7229 | -33.5501 | -29.3042 |
| Total Extraordinary Items | |||||
| Other, Net | -0.04877 | 11.9 | 13.2702 | 4.58184 | |
| Unusual Expense (Income) | 5 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 8.18899 | 17.297 | 10.7968 | 8.18146 | 12.34 |
| Selling/General/Admin. Expenses, Total | 3.94029 | 3.90868 | 4.55406 | 4.07327 | 4.84037 |
| Research & Development | 4.24871 | 13.3883 | 6.24276 | 4.10819 | 2.49964 |
| Operating Income | -8.18899 | -17.297 | -10.7968 | -8.18146 | -12.34 |
| Interest Income (Expense), Net Non-Operating | -0.77751 | -0.67729 | -0.35778 | -0.67798 | -0.7002 |
| Other, Net | 0.18266 | 0.22951 | 0.27555 | 0.07771 | -0.20868 |
| Net Income Before Taxes | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Net Income After Taxes | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Net Income Before Extra. Items | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Net Income | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Income Available to Common Excl. Extra. Items | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Income Available to Common Incl. Extra. Items | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Diluted Net Income | -8.78384 | -17.7448 | -10.8791 | -8.78172 | -13.2489 |
| Diluted Weighted Average Shares | 4.2777 | 4.18156 | 4.15711 | 4.17561 | 4.1752 |
| Diluted EPS Excluding Extraordinary Items | -2.0534 | -4.24359 | -2.61698 | -2.1031 | -3.17324 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -2.0534 | -4.24359 | -2.61698 | -2.1031 | -1.97569 |
| Unusual Expense (Income) | 0 | 0 | 0 | 5 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 60.1811 | 100.205 | 92.0746 | 38.1547 | 44.2403 |
| Cash and Short Term Investments | 59.197 | 97.6471 | 85.4334 | 31.7487 | 41.7485 |
| Cash | 3.80516 | 6.75159 | 1.82578 | 0.88412 | 0.80894 |
| Cash & Equivalents | 13.1976 | 18.255 | 83.6077 | 30.8646 | 40.9395 |
| Total Receivables, Net | 0 | 2.57833 | 2.68107 | ||
| Prepaid Expenses | 0.79162 | 2.36501 | 3.71286 | 3.72493 | 2.49184 |
| Other Current Assets, Total | 0.19248 | 0.19248 | 0.35 | 0 | |
| Total Assets | 66.3119 | 107.73 | 102.295 | 49.1425 | 46.9893 |
| Property/Plant/Equipment, Total - Net | 5.49807 | 7.00181 | 9.31636 | 10.9029 | 2.70521 |
| Property/Plant/Equipment, Total - Gross | 8.59129 | 9.37405 | 11.6652 | 12.3088 | 3.37179 |
| Accumulated Depreciation, Total | -3.09322 | -2.37224 | -2.34884 | -1.40596 | -0.66658 |
| Other Long Term Assets, Total | 0.63277 | 0.52381 | 0.90394 | 0.08497 | 0.04382 |
| Total Current Liabilities | 12.6399 | 17.0075 | 31.8978 | 34.8877 | 18.0893 |
| Accounts Payable | 2.17396 | 1.78228 | 7.38118 | 11.0914 | 6.34534 |
| Accrued Expenses | 7.28012 | 11.2303 | 23.0095 | 23.0437 | 9.85119 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3.14899 | 3.86128 | 0.71016 | 0.75266 | 0.39431 |
| Other Current Liabilities, Total | 0.03687 | 0.13371 | 0.797 | 0 | 1.4985 |
| Total Liabilities | 33.3219 | 38.6222 | 57.02 | 42.9849 | 19.4652 |
| Total Long Term Debt | 15.9844 | 15.6363 | 18.029 | 0 | 0 |
| Other Liabilities, Total | 4.69756 | 5.97842 | 7.09317 | 8.09723 | 1.37589 |
| Total Equity | 32.99 | 69.108 | 45.2749 | 6.15757 | 27.5241 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.00042 | 0.01252 | 0.00989 | 0.00647 | 0.00573 |
| Additional Paid-In Capital | 425.196 | 418.892 | 349.358 | 198.975 | 148.889 |
| Retained Earnings (Accumulated Deficit) | -392.081 | -349.734 | -304.093 | -192.824 | -121.37 |
| Total Liabilities & Shareholders’ Equity | 66.3119 | 107.73 | 102.295 | 49.1425 | 46.9893 |
| Total Common Shares Outstanding | 4.1713 | 4.17395 | 3.29476 | 2.15555 | 1.90806 |
| Accounts Receivable - Trade, Net | 0 | 1.6183 | 2.68107 | ||
| Long Term Debt | 15.9844 | 15.6363 | 18.029 | ||
| Short Term Investments | 42.1943 | 72.6405 | |||
| Other Equity, Total | -0.12609 | -0.06245 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 45.865 | 60.1811 | 67.3478 | 75.238 | 88.4756 |
| Cash and Short Term Investments | 44.227 | 59.197 | 66.2292 | 73.3032 | 86.1212 |
| Cash | 2.89716 | 3.80516 | 3.80611 | 3.98804 | 12.9421 |
| Cash & Equivalents | 4.42728 | 13.1976 | 8.63754 | 21.7826 | 44.0842 |
| Short Term Investments | 36.9026 | 42.1943 | 53.7856 | 47.5326 | 29.0949 |
| Total Receivables, Net | |||||
| Accounts Receivable - Trade, Net | |||||
| Prepaid Expenses | 1.44552 | 0.79162 | 0.92616 | 1.74227 | 2.16186 |
| Other Current Assets, Total | 0.19248 | 0.19248 | 0.19248 | 0.19248 | 0.19248 |
| Total Assets | 51.6453 | 66.3119 | 73.8306 | 82.0666 | 95.6751 |
| Property/Plant/Equipment, Total - Net | 5.12041 | 5.49807 | 5.87229 | 6.24708 | 6.6468 |
| Property/Plant/Equipment, Total - Gross | 8.39551 | 8.59129 | 8.78111 | 8.96512 | 9.21476 |
| Accumulated Depreciation, Total | -3.27509 | -3.09322 | -2.90883 | -2.71803 | -2.56796 |
| Other Long Term Assets, Total | 0.65986 | 0.63277 | 0.61048 | 0.58159 | 0.5527 |
| Total Current Liabilities | 14.3589 | 12.6399 | 17.4692 | 15.6298 | 15.1177 |
| Accounts Payable | 1.32299 | 2.17396 | 1.37422 | 1.98662 | 2.69681 |
| Accrued Expenses | 7.78697 | 7.28012 | 6.07764 | 5.92389 | 6.66826 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 5.21212 | 3.14899 | 9.88364 | 7.58555 | 5.61892 |
| Other Current Liabilities, Total | 0.03687 | 0.03687 | 0.13371 | 0.13371 | 0.13371 |
| Total Liabilities | 35.1863 | 33.3219 | 31.8845 | 32.5968 | 34.5198 |
| Total Long Term Debt | 13.9724 | 15.9844 | 9.38585 | 11.6122 | 13.7284 |
| Long Term Debt | 13.9724 | 15.9844 | 9.38585 | 11.6122 | 13.7284 |
| Other Liabilities, Total | 6.85501 | 4.69756 | 5.02944 | 5.35477 | 5.67369 |
| Total Equity | 16.459 | 32.99 | 41.9461 | 49.4699 | 61.1553 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.00042 | 0.00042 | 0.01253 | 0.01253 | 0.01253 |
| Additional Paid-In Capital | 426.352 | 425.196 | 423.342 | 421.997 | 420.483 |
| Retained Earnings (Accumulated Deficit) | -409.825 | -392.081 | -381.202 | -372.42 | -359.171 |
| Other Equity, Total | -0.06847 | -0.12609 | -0.20687 | -0.11932 | -0.16969 |
| Total Liabilities & Shareholders’ Equity | 51.6453 | 66.3119 | 73.8306 | 82.0666 | 95.6751 |
| Total Common Shares Outstanding | 4.21513 | 4.1713 | 4.17561 | 4.1752 | 4.17478 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -42.3469 | -45.6404 | -111.269 | -71.4537 | -55.6721 |
| Cash From Operating Activities | -37.5444 | -48.1837 | -99.6857 | -45.7207 | -30.0673 |
| Cash From Operating Activities | 0.763 | 0.99982 | 1.12385 | 0.73938 | 0.49394 |
| Non-Cash Items | 8.06298 | 12.1534 | 13.6647 | 12.5179 | 8.10229 |
| Cash Interest Paid | 1.96958 | 1.74088 | 0.62915 | 0.02945 | 0.01044 |
| Changes in Working Capital | -4.02351 | -15.6965 | -3.20492 | 12.4757 | 17.0086 |
| Cash From Investing Activities | 30.0741 | -73.4165 | -0.48449 | -2.74254 | -2.30042 |
| Capital Expenditures | -0.01345 | -0.05417 | -0.48449 | -2.74254 | -2.30042 |
| Cash From Financing Activities | -0.53362 | 60.8234 | 154.875 | 38.4635 | 11.4197 |
| Financing Cash Flow Items | 0 | -1.82044 | -6.03942 | -2.57155 | -0.69018 |
| Issuance (Retirement) of Stock, Net | 0 | 62.5861 | 142.201 | 40.6771 | 12.0527 |
| Issuance (Retirement) of Debt, Net | -0.53362 | 0.05778 | 18.7135 | 0.35798 | 0.05719 |
| Net Change in Cash | -8.00392 | -60.7768 | 54.7047 | -9.99978 | -20.948 |
| Other Investing Cash Flow Items, Total | 30.0876 | -73.3624 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -17.7448 | -42.3469 | -31.4678 | -22.6861 | -9.43724 |
| Cash From Operating Activities | -15.115 | -37.5444 | -30.0895 | -22.8444 | -10.6153 |
| Cash From Operating Activities | 0.18187 | 0.763 | 0.5786 | 0.3878 | 0.19572 |
| Non-Cash Items | 1.22002 | 8.06298 | 6.78652 | 5.24585 | 2.75334 |
| Cash Interest Paid | 0.64146 | 1.96958 | 1.40721 | 0.88743 | 0.431 |
| Changes in Working Capital | 1.22795 | -4.02351 | -5.98672 | -5.79193 | -4.12716 |
| Cash From Investing Activities | 5.5497 | 30.0741 | 18.2944 | 24.2657 | 42.9622 |
| Capital Expenditures | 0 | -0.01345 | -0.01345 | -0.01345 | -0.01345 |
| Other Investing Cash Flow Items, Total | 5.5497 | 30.0876 | 18.3078 | 24.2791 | 42.9756 |
| Cash From Financing Activities | -0.11301 | -0.53362 | -0.76794 | -0.65723 | -0.32713 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03706 | 0 | 0 | 0 | 0 |
| Issuance (Retirement) of Debt, Net | -0.15007 | -0.53362 | -0.76794 | -0.65723 | -0.32713 |
| Net Change in Cash | -9.67828 | -8.00392 | -12.563 | 0.76403 | 32.0197 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Ikarian Capital LLC | Hedge Fund | 4.3462 | 192260 | 0 | 2023-06-30 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0567 | 179456 | 1 | 2023-06-30 | LOW |
| Sio Capital Management, LLC | Hedge Fund | 3.3908 | 150000 | 0 | 2023-06-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.7993 | 79597 | 9069 | 2023-06-30 | LOW |
| Boothbay Fund Management, LLC | Investment Advisor/Hedge Fund | 0.8585 | 37976 | 0 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7429 | 32865 | 0 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7143 | 31600 | 17919 | 2023-06-30 | LOW |
| Andbank Wealth Management, SGIIC, S.A.U. | Investment Advisor | 0.5047 | 22328 | 22328 | 2023-03-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2979 | 13179 | 0 | 2023-06-30 | LOW |
| Moran (Sean F) | Individual Investor | 0.1501 | 6642 | -1 | 2023-03-24 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.1163 | 5143 | 0 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.0758 | 3353 | -12 | 2023-06-30 | LOW |
| Cohen (Yuval) | Individual Investor | 0.074 | 3274 | -1 | 2023-03-24 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 0.0716 | 3168 | -319 | 2023-06-30 | MED |
| Dorsey, Wright & Associates, LLC | Investment Advisor/Hedge Fund | 0.0578 | 2555 | 2555 | 2023-06-30 | HIGH |
| Group One Trading, L.P. | Research Firm | 0.0462 | 2045 | -220 | 2023-06-30 | HIGH |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.0424 | 1876 | 0 | 2023-06-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.0368 | 1629 | 0 | 2023-06-30 | LOW |
| Catlin (Avery W) | Individual Investor | 0.0354 | 1567 | 0 | 2023-03-24 | |
| RBC Capital Partners | Investment Advisor | 0.0342 | 1512 | 1512 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Corbus Pharmaceuticals Company profile
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.| Industry: | Bio Therapeutic Drugs |
500 River Ridge Drive
NORWOOD
MASSACHUSETTS 02062
US
Income Statement
- Annual
- Quarterly
News
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com